Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2009 - 2018)

Alnylam Pharmaceuticals' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $3.2 million for Q1 2018.

• Quarterly Depreciation & Amortization (CF) rose 5.93% year-over-year to $3.2 million in Q1 2018, while the trailing twelve-month figure through Dec 2018 was $3.2 million (down 76.23% YoY) and the FY2025 annual result came in at $54.8 million, down 0.54% from the prior year.
• Depreciation & Amortization (CF) was $3.2 million for Q1 2018 at Alnylam Pharmaceuticals, down from $3.7 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $5.3 million in Q3 2015 and bottomed at $2.6 million in Q1 2014.
• A 5-year average of $3.7 million and a median of $3.5 million in 2016 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2015 — Depreciation & Amortization (CF) surged 75.07% — and 2016, when it plunged 40.46%.
• Alnylam Pharmaceuticals' Depreciation & Amortization (CF) stood at $3.3 million in 2014, then soared by 51.72% to $5.1 million in 2015, then plunged by 40.46% to $3.0 million in 2016, then grew by 23.06% to $3.7 million in 2017, then declined by 14.43% to $3.2 million in 2018.
• Business Quant data shows ALNY's Depreciation & Amortization (CF) at $3.2 million in Q1 2018, $3.7 million in Q4 2017, and $3.6 million in Q3 2017.